It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Rhabdomyolysis is a risk factor for acute kidney injury, transition towards chronic kidney disease, and death. The role of calcium phosphate deposits in the mechanisms of rhabdomyolysis-induced acute kidney injury (RAKI) is still unclear. Better insight of the role calcium in RAKI could lead to new therapeutic avenues. Here, we show in a mice model of RAKI that calcium phosphate deposits were frequent in the kidney (hydroxyapatite) and partly correlated with the severity of the kidney injury. However, the intensity of deposits was highly heterogeneous between mice. Treatment with sodium chloride, sodium bicarbonate or inorganic pyrophosphate (PPi; an inhibitor of the calcium phosphate crystallization), or combinations thereof, did not improve kidney outcomes and hydroxyapatite deposition during RAKI. Unexpectedly, Abcc6 knockout mice (ko), characterized by PPi deficiency, developed less severe RAKI despite similar rhabdomyolysis severity, and had similar hydroxyapatite deposition suggesting alternative mechanisms. This improved kidney outcome at day 2 translated to a trend in improved glomerular filtration rate at month 2 in Abcc6-/-mice and to significantly less interstitial fibrosis. In addition, whereas the pattern of infiltrating cells at day 2 was similar between wt and ko mice, kidneys of Abcc6-/- mice were characterized by more CD19+ B-cells, less CD3+ T-cells and a lower R1/R2 macrophage ratio at month 2. In summary, kidney calcium phosphate deposits are frequent in RAKI but hydration with sodium bicarbonate or sodium chloride does not modify the kidney outcome. Blocking ABCC6 emerges as a new option to prevent RAKI and subsequent transition toward kidney fibrosis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University Hospital of Toulouse, Department of Nephrology and Organ Transplantation, Reference Centre for Rare Kidney Diseases (SORARE), French Intensive Care Renal Network (FIRN), Toulouse Cedex, France (GRID:grid.411175.7) (ISNI:0000 0001 1457 2980); Rangueil Hospital, National Institute of Health and Medical Research (INSERM), Institute of Metabolic and Cardiovascular Diseases (I2MC), UMR 1297, Toulouse, France (GRID:grid.414295.f) (ISNI:0000 0004 0638 3479); University Toulouse-3, Toulouse, France (GRID:grid.508721.9)
2 Tenon Hospital, National Institute of Health and Medical Research, (INSERM) UMR S 1155, Paris, France (GRID:grid.413483.9) (ISNI:0000 0001 2259 4338); Sorbonne University, Paris, France (GRID:grid.462844.8) (ISNI:0000 0001 2308 1657); Assistance Publique – Hôpitaux de Paris, Department of Physiology, Tenon Hospital, Paris, France (GRID:grid.50550.35) (ISNI:0000 0001 2175 4109)
3 University Hospital of Toulouse, Department of Nephrology and Organ Transplantation, Reference Centre for Rare Kidney Diseases (SORARE), French Intensive Care Renal Network (FIRN), Toulouse Cedex, France (GRID:grid.411175.7) (ISNI:0000 0001 1457 2980); Rangueil Hospital, National Institute of Health and Medical Research (INSERM), Institute of Metabolic and Cardiovascular Diseases (I2MC), UMR 1297, Toulouse, France (GRID:grid.414295.f) (ISNI:0000 0004 0638 3479)
4 Assistance Publique – Hôpitaux de Paris, Department of Physiology, Tenon Hospital, Paris, France (GRID:grid.50550.35) (ISNI:0000 0001 2175 4109)
5 University Paris XI, Laboratory of Chemistry and Physics, CNRS UMR 8000, Orsay, France (GRID:grid.5842.b) (ISNI:0000 0001 2171 2558)
6 Rangueil Hospital, National Institute of Health and Medical Research (INSERM), Institute of Metabolic and Cardiovascular Diseases (I2MC), UMR 1297, Toulouse, France (GRID:grid.414295.f) (ISNI:0000 0004 0638 3479)
7 Rangueil Hospital, National Institute of Health and Medical Research (INSERM), Institute of Metabolic and Cardiovascular Diseases (I2MC), UMR 1297, Toulouse, France (GRID:grid.414295.f) (ISNI:0000 0004 0638 3479); Assistance Publique – Hôpitaux de Paris, Department of Physiology, Tenon Hospital, Paris, France (GRID:grid.50550.35) (ISNI:0000 0001 2175 4109)
8 University Hospital of Toulouse, Department of Nephrology and Organ Transplantation, Reference Centre for Rare Kidney Diseases (SORARE), French Intensive Care Renal Network (FIRN), Toulouse Cedex, France (GRID:grid.411175.7) (ISNI:0000 0001 1457 2980); Rangueil Hospital, National Institute of Health and Medical Research (INSERM), Institute of Metabolic and Cardiovascular Diseases (I2MC), UMR 1297, Toulouse, France (GRID:grid.414295.f) (ISNI:0000 0004 0638 3479); Assistance Publique – Hôpitaux de Paris, Department of Physiology, Tenon Hospital, Paris, France (GRID:grid.50550.35) (ISNI:0000 0001 2175 4109)